Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
13 mars 2023 08h00 HE
|
Aridis Pharmaceuticals, Inc.
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif.,...